Salute e Benessere

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved…

Ad hoc announcement pursuant to Art. 53 LR Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids Significantly lower rate of vertebral fractures reported with AGAMREE Lower incidence of cataracts than normally seen for DMD patients on corticosteroids Pratteln, Switzerland, November 4, 2025– Santhera Pharmaceuticals (SIX: SANN) today...

Coloplast A/S - Full-Year Financial Results 2024/25

2024/25 Full year financial results1 October 2024 - 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin 1of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and the Skin Care divestment.• Organic growth rates by business area: Ostomy Care 7%, Continence Care 9%, Voice & Respiratory Care 9%, Wound & Tissue Repair 5% and Interventional Urology 2%. • Growth in Ostomy Care was broad based with good contribution from recent...

Zelluna ASA: Disclosure of large shareholding

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), divided on a first tranche of 3,729,774 new shares ("Tranche 1") and a second tranche of 1,770,226 new shares, and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform (the "Retail Offering"). Radforsk…

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate…

Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trialshowcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patients V-INCEPTION analyses highlight Leqvio adherence and goal attainment data when initiated early in post-acute coronary syndrome patientsLp(a)...

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer Inc. in Europe exceeded the threshold triggering a USD 30 million sales milestone payment...

Zelluna ASA – Ex. date

The shares in Zelluna ASA will from today, 4 November 2025, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 3 November 2025.This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika…

Immune response successfully improved with second generation vaccine candidateSaint-Herblain (France), November 4, 2025 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive results of its Phase 1 clinical trial investigating the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). The randomized controlled Phase 1 trial, VLA1601-102, enrolled approximately...

Philips continues momentum; delivers strong order intake, step-up in sales…

November 4, 2025Q3 2025 Group HighlightsComparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA margin increased by 50 basis points to 12.3% of salesOperating cash flow of EUR 327 million, with a free cash flow of EUR 172 millionPhilips reiterates full-year 2025 outlook, with margin now expected at the upper end of the rangeRoy Jakobs, CEO of Royal...

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved…

Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids Significantly lower rate of vertebral fractures reported with AGAMREE Lower incidence of cataracts than normally seen for DMD patients on corticosteroids Pratteln, Switzerland, November 4, 2025– Santhera Pharmaceuticals (SIX: SANN) today reported positive topline results from an analysis...

ICP DAS-BMP Redefines Medical Material Performance with Low-Migration and…

The low-migration Arothane™ ARP-B20 TPU is ISO 10993 compliant and suitable for implantation up to 90 days. It minimizes additive migration during processing, helping catheters retain smooth surfaces throughout their shelf life, while offering 15 color options for flexible and customized design. The low-migration Arothane™ ARP-B20 TPU is ISO 10993 compliant and suitable for implantation up to 90 days. It minimizes additive migration during processing, helping catheters retain smooth surfaces...

Zelluna ASA – Key information relating to subsequent offering

Reference is made to the stock exchange announcement made by Zelluna ASA (the " Company ") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the " Private Placement "), the allocation of 315,639 new shares in a retail offering via the PrimaryBid platform (the " PrimaryBidOffering "), and a potential subsequent repair offering of up to 800,000 new shares at the same subscription price as in the Private…

Zelluna ASA - Mandatory notification of trade

Reference is made to the private placement (the " Private Placement ") and the retail offering through PrimaryBid (the " PrimaryBid Offering ") announced by Zelluna ASA on 3 November 2025. Please see the attached PDMR-forms related to (i) allocation of shares in the Private Placement; and (ii) share lending to facilitate settlement of tranche 1 of the Private Placement and the PrimaryBid Offering. Attachment 20251104 - PDMR attachment

Zelluna ASA - Successful private placement and retail offering

Successful private placement and retail offering - Zelluna ASA raises NOK 58 million to advance the world’s first “off-the-shelf” TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials and develop the pipelineStrong support from existing shareholders, management and board members with extensive life science and cell therapy experience.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S...

Chronic Progressive Multiple Sclerosis Market to Witness Accelerated Expansion…

Chronic Progressive Multiple Sclerosis Market Summary Chronic Progressive Multiple Sclerosis Market Summary Discover the chronic progressive multiple sclerosis new treatment @New Treatments for Chronic Progressive Multiple Sclerosis Key Factors Driving the Growth of the Chronic Progressive Multiple Sclerosis Market Rising Multiple Sclerosis Prevalence The global prevalence of multiple sclerosis is increasing, with earlier and more accurate diagnoses facilitated by...

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial…

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and...

Information Regarding the Total Number of Voting Rights and Total Number of…

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of theAutorité des Marchés Financiers )Market : NYSE Euronext ParisISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights10/31/2025 179,827,919 Total gross of voting rights: 179,827,919 Total net* of voting rights: 179,741,847 ...

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

PARIS and CAMBRIDGE, Mass., Nov.03, 2025(GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “ Company ”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: UBS Global Healthcare ConferenceDate: Monday, November 10, 2025 Time: 5pm ET / 11pm CET...

Nyxoah to Participate in the Stifel 2025 Healthcare Conference

Nyxoah to Participate in the Stifel 2025 Healthcare ConferenceMont-Saint-Guibert, Belgium – November 3, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Stifel 2025 Healthcare Conference on Tuesday, Nov. 11, 2025. The Company is scheduled to present at 9:20am Eastern Time the same day via webcast...

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphomaTwo abstracts featuring new Phase 2 data highlight the potential of CAR-T cell therapy candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Results demonstrate high rates of complete and durable responses along with low rates of high-grade toxicities using GLPG5101 manufactured on innovative median seven-day vein-to-vein time platform,...

CQ Medical® Appoints Michael Galbus as Chief Executive Officer, Mike Sutter as…

Michael brings more than 30 years of leadership experience across highly regulated industries, including aerospace, building products, chemicals, and medical devices. He has learned to quickly identify what makes organizations in different sectors succeed and has applied those insights to deliver performance and growth. His leadership journey has included senior roles at global companies such as Dow Inc., Saint-Gobain, Zodiac Aerospace, and ACTEGA, culminating in his appointment as CEO of CQ…

Oxurion ends discussions regarding previously announced preclinical transaction…

Leuven, BELGIUM, November 3, 2025, 6:00 PM – Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, announces the termination of discussions regarding the planned acquisition of a company specialized in preclinical microbiology services (see press release dated June 19, 2025 – link)…

Oxurion beëindigt gesprekken over eerder aangekondigde preklinische overname en…

Leuven, BELGIË, 3 november 2025, 18u00 – Oxurion NV (Euronext Brussel: OXUR) een farmaceutische onderaannemingsvennootschap gevestigd in Leuven, maakt bekend dat het de gesprekken heeft beëindigd met betrekking tot de overwogene overname van een vennootschap gespecialiseerd in preklinische microbiologische diensten (zie persbericht van 19 juni 2025 – link)…

Traditional Wound Care Products Market Driven by Rising Chronic Wound Cases, and…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=287622 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=287622 202 - Pages 126 – Tables37 – Figures Scope Of The Report Traditional Wound Care Products Market Overview 1. Rising Prevalence of Chronic and Acute Wounds The Traditional Wound Care Products Market continues to expand due to the increasing prevalence of chronic wounds such as...

Zelluna ASA – Contemplates private placement

Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapyNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Oslo, 3...

Altri Comunicati